Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers

Analytical Biochemistry

Volumn 362, Issue 1, 2007, Pages 44-54

  Whiteaker, Jeffrey R ^a   Zhao, Lei ^a   Zhang, Heidi Y ^a   Feng, Li Chia ^a   Piening, Brian D ^a   Anderson, Leigh ^b   Paulovich, Amanda G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b The Plasma Proteome Institute   (United States)

Author keywords

Antipeptide antibody; Biomarkers; LC MS MS; Peptide quantitation; Stable isotope dilution; Targeted proteomics

Indexed keywords

ANTIBODIES; ISOTOPES; MASS SPECTROMETRY; PEPTIDES; PROTEOMICS;

ANTI-PEPTIDE ANTIBODIES; CLINICAL APPLICATION; CLINICAL DIAGNOSTICS; IMMOBILIZED ANTIBODIES; LC/MS/MS; PROTEIN CONCENTRATIONS; STABLE ISOTOPE DILUTION; TARGETED PROTEOMICS;

BIOMARKERS;

BIOLOGICAL MARKER; IMMOBILIZED ANTIBODY; PEPTIDE DERIVATIVE;

ACCURACY; ANALYTIC METHOD; ARTICLE; HUMAN; ISOTOPE DILUTION ASSAY; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEOMICS; REPRODUCIBILITY; STOICHIOMETRY; VALIDATION PROCESS;

EID: 33846665857     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2006.12.023     Document Type: Article

References (36)

1. Clemons M., Danson S., and Howell A. Tamoxifen ("Nolvadex"): a review. Cancer Treat. Rev. 28 (2002) 165-180
2. Haber D.A., Bell D.W., Sordella R., Kwak E.L., Godin-Heymann N., Sharma S.V., Lynch T.J., and Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70 (2005) 419-426
3. Ligibel J.A., and Winer E.P. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin. Oncol. 29 (2002) 38-43
4. Shawver L.K., Slamon D., and Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 (2002) 117-123
5. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connolly J.L., Hayes D.F., Edge S.B., Lichter A., and Schnitt S.J. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124 (2000) 966-978
6. Ross J.S., and Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16 (1998) 413-428
7. Anderson N.L., and Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1 (2002) 845-867
8. Want E.J., Cravatt B.F., and Siuzdak G. The expanding role of mass spectrometry in metabolite profiling and characterization. Chembiochem 6 (2005) 1941-1951
9. Chace D.H., and Kalas T.A. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin. Biochem. 38 (2005) 296-309
10. Fenn J.B., Mann M., Meng C.K., Wong S.F., and Whitehouse C.M. Electrospray ionization for mass spectrometry of large biomolecules. Science 246 (1989) 64-71
11. Karas M., and Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 60 (1988) 2299-2301
12. Barr J.R., Maggio V.L., Patterson Jr. D.G., Cooper G.R., Henderson L.O., Turner W.E., Smith S.J., Hannon W.H., Needham L.L., and Sampson E.J. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 42 (1996) 1676-1682
13. Gerber S.A., Rush J., Stemman O., Kirschner M.W., and Gygi S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA 100 (2003) 6940-6945
14. Kuster B., Schirle M., Mallick P., and Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat. Rev. Mol. Cell. Biol. 6 (2005) 577-583
15. Aguiar M., Masse R., and Gibbs B.F. Mass spectrometric quantitation of C-reactive protein using labeled tryptic peptides. Anal. Biochem. 354 (2006) 175-181
16. Anderson L., and Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteom. 5 (2006) 573-588
17. Barnidge D.R., Goodmanson M.K., Klee G.G., and Muddiman D.C. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 3 (2004) 644-652
18. Berna M., Schmalz C., Duffin K., Mitchell P., Chambers M., and Ackermann B. Online immunoaffinity liquid chromatography/tandem mass spectrometry determination of a type II collagen peptide biomarker in rat urine: Investigation of the impact of collision-induced dissociation fluctuation on peptide quantitation. Anal. Biochem. (2006)
19. 13C-labeled peptide standards. Proteomics 4 (2004) 1175-1186
20. Pan S., Zhang H., Rush J., Eng J., Zhang N., Patterson D., Comb M.J., and Aebersold R. High throughput proteome screening for biomarker detection. Mol. Cell. Proteom. 4 (2005) 182-190
21. Wu S.L., Amato H., Biringer R., Choudhary G., Shieh P., and Hancock W.S. Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system. J. Proteome Res. 1 (2002) 459-465
22. Anderson N.L., Anderson N.G., Haines L.R., Hardie D.B., Olafson R.W., and Pearson T.W. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 3 (2004) 235-244
23. Safarik I., and Safarikova M. Magnetic techniques for the isolation and purification of proteins and peptides. Biomagn. Res. Technol. 2 (2004) 7
24. Lin S., Shaler T.A., and Becker C.H. Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. Anal. Chem. 78 (2006) 5762-5767
25. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., and Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17 (1999) 994-999
26. Gygi S.P., Rist B., Griffin T.J., Eng J., and Aebersold R. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J. Proteome Res. 1 (2002) 47-54
27. Molloy M.P., Donohoe S., Brzezinski E.E., Kilby G.W., Stevenson T.I., Baker J.D., Goodlett D.R., and Gage D.A. Large-scale evaluation of quantitative reproducibility and proteome coverage using acid cleavable isotope coded affinity tag mass spectrometry for proteomic profiling. Proteomics 5 (2005) 1204-1208
28. Sakai J., Kojima S., Yanagi K., and Kanaoka M. 18O-labeling quantitative proteomics using an ion trap mass spectrometer. Proteomics 5 (2005) 16-23
29. Skeel A., and Leonard E.J. alpha 1-Antichymotrypsin is the human plasma inhibitor of macrophage ectoenzymes that cleave pro-macrophage stimulating protein. J. Biol. Chem. 276 (2001) 21932-21937
30. U.S. Department of Health and Human Services, Guidance for Industry: Bioanalytical Method Validation, 2001.
31. Brand J., Haslberger T., Zolg W., Pestlin G., and Palme S. Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics 6 (2006) 3236-3242
32. Butcher S.P. Target discovery and validation in the post-genomic era. Neurochem. Res. 28 (2003) 367-371
33. Lindsay M.A. Target discovery. Nat. Rev. Drug Discov. 2 (2003) 831-838
34. L. Hartwell, E. Lander, Report to National Cancer Advisory Board, NCAB Working Group on Biomedical Technology, 2005.
35. Adler M. Immuno-PCR as a clinical laboratory tool. Adv. Clin. Chem. 39 (2005) 239-292
36. Niemeyer C.M., Adler M., and Wacker R. Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol. 23 (2005) 208-216